Schein Subsidiary Marsam To Resume Manufacturing In Fourth Quarter
Executive Summary
Schein subsidiary Marsam Pharmaceuticals expects to partially resume manufacturing by the end of 1999 after voluntarily suspending all manufacturing and testing at its Cherry Hill, N.J. facility.
You may also be interested in...
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.
Watson To Acquire Schein: Generic Business Projected At $800 Mil. In 2001
Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.